Next generation gene therapy

unlocking the potential | expanding the boundaries

Amarna Therapeutics has developed a groundbreaking non-immunogenic viral platform to deliver any transgene of choice into humans. It is advancing a pipeline of transformative, potentially curative gene therapies for a range of rare and prevalent diseases, including monogenetic indications, autoimmune diseases and chronic inflammation.

Latest news
Jul 8, 2025
Amarna Therapeutics and NorthX Biologics Finalize Agreement to Advance Nimvec™ AM510 Gene Therapy Toward Clinical Trials for Type 1 Diabetes